GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigen Biotechnology Corp (ROCO:3176) » Definitions » Median PS Value

Medigen Biotechnology (ROCO:3176) Median PS Value : NT$136.50 (As of Jun. 05, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Medigen Biotechnology Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Medigen Biotechnology's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was NT$8.944. Medigen Biotechnology's 10-Year median PS Ratio is 15.2616. Therefore, the Median PS Value for today is NT$136.50.

As of today (2024-06-05), Medigen Biotechnology's share price is NT$43.70. Medigen Biotechnology's Median PS Value is NT$136.50. Therefore, Medigen Biotechnology's Price to Median PS Value for today is 0.32.

The historical rank and industry rank for Medigen Biotechnology's Median PS Value or its related term are showing as below:

ROCO:3176' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.07   Med: 0.34   Max: 0.81
Current: 0.32

During the past 13 years, the highest Price to Median PS Value of Medigen Biotechnology was 0.81. The lowest was 0.07. And the median was 0.34.

ROCO:3176's Price-to-Median-PS-Value is ranked better than
80.08% of 261 companies
in the Biotechnology industry
Industry Median: 0.67 vs ROCO:3176: 0.32

Medigen Biotechnology Median PS Value Historical Data

The historical data trend for Medigen Biotechnology's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medigen Biotechnology Median PS Value Chart

Medigen Biotechnology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Median PS Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 112.10 111.69 687.20 142.36 132.43

Medigen Biotechnology Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 97.57 97.55 123.48 132.43 136.50

Competitive Comparison of Medigen Biotechnology's Median PS Value

For the Biotechnology subindustry, Medigen Biotechnology's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medigen Biotechnology's Price-to-Median-PS-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medigen Biotechnology's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Medigen Biotechnology's Price-to-Median-PS-Value falls into.



Medigen Biotechnology Median PS Value Calculation

Medigen Biotechnology's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=8.944*15.2616
=136.50

10-Year Median PS Ratio is 15.2616.
Medigen Biotechnology's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$8.944.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medigen Biotechnology  (ROCO:3176) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Medigen Biotechnology's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=43.70/136.50
=0.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medigen Biotechnology Median PS Value Related Terms

Thank you for viewing the detailed overview of Medigen Biotechnology's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Medigen Biotechnology (ROCO:3176) Business Description

Traded in Other Exchanges
N/A
Address
Yuancyu Street, 14F, Building No.3,, Nangang District, Taipei, TWN, 11560
Medigen Biotechnology Corp is a biopharmaceutical company primarily engaged in new drug development, drug discovery, molecular diagnostics, vaccine, and generic drugs. The new drug development business focuses mainly on the clinical stage of drug development and includes PI-88 MUPAFOSTAT for the treatment of liver cancer and OBP-301 treatment using adenovirus targeted to cancer cells only. Drug discovery includes the development of human-native mAbs for therapeutic applications related to infectious diseases. Generic drugs include pharmaceuticals for infectious diseases (antibiotics), contraceptives, nutrition milk powder, vitamin C tablets, dermatologic agents, and eye care products.

Medigen Biotechnology (ROCO:3176) Headlines

No Headlines